Affinity Asset Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-50,000
Closed -$4.2M – 121
2026
Q1
$4.2M Buy
+50,000
New +$2.9M 0.22% 77

Other funds holding DNTH

Affinity Asset Advisors's DNTH Position: Q3 2026 in Review

Affinity Asset Advisors reduced its Dianthus Therapeutics (DNTH) stake by 13% in Q3 2026, selling an estimated $5.19M and leaving 350,000 shares worth $30.8M. The position accounts for 1.25% of the portfolio, ranked #23.

Affinity Asset Advisors first reported a position in DNTH in Q3 2025 and has held it in 5 quarters since. The position peaked at $39M in Q2 2026. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • Affinity Asset Advisors held 350,000 shares of Dianthus Therapeutics worth $30.8M as of Q3 2026.
  • Affinity Asset Advisors sold 50,000 Dianthus Therapeutics shares in Q3 2026, an estimated $5.19M.
  • Dianthus Therapeutics made up 1.25% of Affinity Asset Advisors's portfolio in Q3 2026, its #23 holding.
  • Affinity Asset Advisors first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Affinity Asset Advisors's Dianthus Therapeutics position peaked at $39M in Q2 2026.
  • 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.